PURPOSE: To examine the association of cardiovascular disease (CVD), CVD risk factors, and CVD treatment with age-related macular degeneration (AMD). DESIGN: Observational analysis of a randomized clinical trial. SETTINGS: The Women's Health Initiative Sight Examination (WHISE), an ancillary study to the Women's Health Initiative's clinical trial of hormone replacement therapy. STUDY POPULATION: A total of 4,288 women age 63 years and older. OBSERVATION PROCEDURES: Information on CVD and its risk factors were obtained from a standardized questionnaire and examination. MAIN OUTCOME MEASURE: AMD as determined by standardized grading of fundus photographs. RESULTS:Prevalence of any AMD was 21.4% (n = 919). Of those with AMD, 5.8% (n = 53) had signs of exudative AMD (n = 39) or pure geographic atrophy (n = 14), limiting the power to examine associations. Significant associations between late AMD and CVD risk factors were (odds ratio [OR], 95% confidence interval [CI]) older age (1.19, 1.13 to 1.27, P < .0001), more pack years smoked (1.02 per pack-year smoked, 1.003 to 1.03, P = .01), systolic blood pressure (0.84 per 10 mm Hg, 0.71 to 0.995, P = .04), report of taking calcium channel blockers (2.49, 1.21 to 5.12, P = .04), self-reported history of diabetes (2.00, 1.01 to 3.96, P = .05), and greater body mass index (1.05 per 1 kg/m, 1.001 to 1.10, P = .05). History of myocardial infarction, stroke, use of statins, or white blood cell count was not associated with AMD. CONCLUSIONS: Results suggest that smoking, use of calcium channel blockers, diabetes, and obesity are risk factors for late AMD in women. However, the association of late AMD with systolic blood pressure and the effects of other CVD risk factors on early AMD need to be further explored.
RCT Entities:
PURPOSE: To examine the association of cardiovascular disease (CVD), CVD risk factors, and CVD treatment with age-related macular degeneration (AMD). DESIGN: Observational analysis of a randomized clinical trial. SETTINGS: The Women's Health Initiative Sight Examination (WHISE), an ancillary study to the Women's Health Initiative's clinical trial of hormone replacement therapy. STUDY POPULATION: A total of 4,288 women age 63 years and older. OBSERVATION PROCEDURES: Information on CVD and its risk factors were obtained from a standardized questionnaire and examination. MAIN OUTCOME MEASURE: AMD as determined by standardized grading of fundus photographs. RESULTS: Prevalence of any AMD was 21.4% (n = 919). Of those with AMD, 5.8% (n = 53) had signs of exudative AMD (n = 39) or pure geographic atrophy (n = 14), limiting the power to examine associations. Significant associations between late AMD and CVD risk factors were (odds ratio [OR], 95% confidence interval [CI]) older age (1.19, 1.13 to 1.27, P < .0001), more pack years smoked (1.02 per pack-year smoked, 1.003 to 1.03, P = .01), systolic blood pressure (0.84 per 10 mm Hg, 0.71 to 0.995, P = .04), report of taking calcium channel blockers (2.49, 1.21 to 5.12, P = .04), self-reported history of diabetes (2.00, 1.01 to 3.96, P = .05), and greater body mass index (1.05 per 1 kg/m, 1.001 to 1.10, P = .05). History of myocardial infarction, stroke, use of statins, or white blood cell count was not associated with AMD. CONCLUSIONS: Results suggest that smoking, use of calcium channel blockers, diabetes, and obesity are risk factors for late AMD in women. However, the association of late AMD with systolic blood pressure and the effects of other CVD risk factors on early AMD need to be further explored.
Authors: Ronald Klein; Barbara E K Klein; Emily K Marino; Lewis H Kuller; Curt Furberg; Gregory L Burke; Larry D Hubbard Journal: Ophthalmology Date: 2003-01 Impact factor: 12.079
Authors: Kylee L Spencer; Lana M Olson; Nathalie Schnetz-Boutaud; Paul Gallins; Gaofeng Wang; William K Scott; Anita Agarwal; Johanna Jakobsdottir; Yvette Conley; Daniel E Weeks; Michael B Gorin; Margaret A Pericak-Vance; Jonathan L Haines Journal: Invest Ophthalmol Vis Sci Date: 2011-03-28 Impact factor: 4.799
Authors: M Haan; M A Espeland; B E Klein; R Casanova; S A Gaussoin; R D Jackson; A E Millen; S M Resnick; J E Rossouw; S A Shumaker; R Wallace; K Yaffe Journal: Neurology Date: 2012-03-14 Impact factor: 9.910
Authors: Niyati Parekh; Rickie P Voland; Suzen M Moeller; Barbara A Blodi; Cheryl Ritenbaugh; Richard J Chappell; Robert B Wallace; Julie A Mares Journal: Arch Ophthalmol Date: 2009-11
Authors: Jennyfer Zerbib; Johanna M Seddon; Florence Richard; Robyn Reynolds; Nicolas Leveziel; Pascale Benlian; Patrick Borel; Josué Feingold; Arnold Munnich; Gisèle Soubrane; Josseline Kaplan; Jean-Michel Rozet; Eric H Souied Journal: PLoS One Date: 2009-10-05 Impact factor: 3.240